Literature DB >> 16041895

The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults.

Robert Burgoyne1, Evan Collins, Cheryl Wagner, Susan Abbey, Mark Halman, Margaret Nur, Sharon Walmsley.   

Abstract

OBJECTIVES: To investigate the relationship between lipodystrophy-specific symptom severity and wellbeing.
METHODS: HIV-positive adult patients with body fat redistribution (lipodystrophy syndrome) associated with antiretroviral therapy reported their total non-lipodystrophy symptoms and side effects and completed measures assessing body fat changes (yielding Atrophy, Hypertrophy and Total Lipodystrophy scores), mental health and quality of life. Effects of total symptom complex and lipodystrophy severity on quality of life and mental health were analyzed using Spearman's rho correlations. Logistic regression analyses were utilized to determine the relative-odds of depression produced by overall symptom count and lipodystrophy score increments.
RESULTS: Mean ratings for Hypertrophy and Atrophy corresponded to 'very mild' and 'mild' degrees of severity, respectively. The total symptom complex was associated with ratings for most of the mental health and quality of life measures. Patient-perceived body image scores were the sole study variable responsive to lipodystrophy severity ratings. In comparison to reference norms, a pronounced degree of body image impairment was evident.
CONCLUSION: Although responsive to the total symptom profile, psychosocial measures typically utilized for evaluating quality of life and mental health status in HIV disease lacked sensitivity and specificity for measuring the consequences of lipodystrophy-associated fat distribution changes alone. Lipodystrophy severity did impact negatively on body image.

Entities:  

Mesh:

Year:  2005        PMID: 16041895     DOI: 10.1007/s11136-004-2580-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  35 in total

1.  Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection.

Authors:  Leslie A Lenert; Martin Feddersen; Ann Sturley; Daniel Lee
Journal:  Am J Med       Date:  2002-08-15       Impact factor: 4.965

2.  Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile.

Authors:  Robert W Burgoyne; Sean B Rourke; Dean M Behrens; Irving E Salit
Journal:  AIDS Behav       Date:  2004-06

3.  Clinical importance of provider-reported HIV symptoms compared with patient-report.

Authors:  A C Justice ; C H Chang ; L Rabeneck; R Zackin
Journal:  Med Care       Date:  2001-04       Impact factor: 2.983

4.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

5.  A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey.

Authors:  X Badia; D Podzamczer; M Garcia; C López-Lavid C; E Consiglio
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

Review 6.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

Review 7.  Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.

Authors:  R W Shafer; D A Vuitton
Journal:  Biomed Pharmacother       Date:  1999-03       Impact factor: 6.529

8.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Authors:  K V Heath; R S Hogg; K J Chan; M Harris; V Montessori; M V O'Shaughnessy; J S Montanera
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

9.  Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV Overview of Problems--Evaluation System (HOPES).

Authors:  P A Ganz; C A Coscarelli Schag; B Kahn; L Petersen; K Hirji
Journal:  Qual Life Res       Date:  1993-04       Impact factor: 4.147

10.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

View more
  20 in total

Review 1.  Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

Authors:  Gabriele Arendt
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV.

Authors:  Marisela Noorhasan; Daniel R Drozd; Carl Grunfeld; Joseph O Merrill; Greer A Burkholder; Michael J Mugavero; James H Willig; Amanda L Willig; Karen L Cropsey; Kenneth H Mayer; Aaron Blashill; Matthew Mimiaga; Mary E McCaul; Heidi Hutton; Geetanjali Chander; William C Mathews; Sonia Napravnik; Joseph J Eron; Katerina Christopoulos; Rob J Fredericksen; Robin M Nance; Joseph Chris Delaney; Paul K Crane; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

3.  Mobile Health Technology for Improving Symptom Management in Low Income Persons Living with HIV.

Authors:  Rebecca Schnall; Hwayoung Cho; Alexander Mangone; Adrienne Pichon; Haomiao Jia
Journal:  AIDS Behav       Date:  2018-10

4.  Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.

Authors:  E Jennifer Edelman; Kirsha Gordon; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  AIDS Patient Care STDS       Date:  2012-05-21       Impact factor: 5.078

5.  Symptom Profile and Technology Use of Persons Living With HIV Who Access Services at a Community-Based Organization in the Deep South.

Authors:  Rebecca Schnall; Karen Musgrove; D Scott Batey
Journal:  J Assoc Nurses AIDS Care       Date:  2020 Jan-Feb       Impact factor: 1.354

6.  Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients.

Authors:  P F Grima; R Chiavaroli; P Grima
Journal:  Radiol Med       Date:  2008-10-25       Impact factor: 3.469

7.  The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

Authors:  Siddharth H Sheth; Robin J Larson
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

Review 8.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Body image in older men with or at-risk for HIV infection.

Authors:  A Sharma; A A Howard; R S Klein; E E Schoenbaum; D Buono; M P Webber
Journal:  AIDS Care       Date:  2007-02

10.  Severity of lipodystrophy is associated with decreased health-related quality of life.

Authors:  Giovanni Guaraldi; Rita Murri; Gabriella Orlando; Chiara Giovanardi; Nicola Squillace; Marcella Vandelli; Barbara Beghetto; Giulia Nardini; Maria De Paola; Roberto Esposito; Albert W Wu
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.